PMID: 7334458Oct 1, 1981Paper

Pharmacokinetic study of sisomicin in humans

Journal of Pharmacokinetics and Biopharmaceutics
M ChungS Symchowicz

Abstract

Detailed analyses of the pharmacokinetics of sisomicin administered at doses of 25, 50 and 100 mg intravenously and intramuscularly to healthy volunteers established that the drug is handled by a two-compartment open model system with a disposition (elimination) half-life of 2.6 hr. The kinetic estimates over this dose range are linear and independent of dose and were verified by a 60-min infusion experiment in which dose and the maximum serum concentration achieved (5 microgram/ml) were predicted correctly. Sisomicin was rapidly distributed to the tissue compartment, and equilibrium between the central and the tissue compartment was established by 30 min after dosing. Renal clearance (55 ml/min) of sisomicin was about 30% less than total body clearance (78 ml/min). Total urinary excretion of sisomicin during a 24-hr period following drug administration was about 70% of the dose. The disposition kinetics of sisomicin following intramuscular administration are similar to those obtained following rapid intravenous administration. Intramuscular bioavailability of sisomicin for the doses of 25, 50, and 100 mg was greater than 95%. Based on these results, various initial loading infusion doses and maintenance infusion rates were cal...Continue Reading

References

Nov 1, 1979·European Journal of Clinical Pharmacology·M WenkF Follath
Dec 1, 1977·Journal of Pharmacokinetics and Biopharmaceutics·J J SchentagL M Gerbracht
Sep 1, 1977·The American Journal of the Medical Sciences·R FeldV Rodriguez
May 1, 1978·Clinical Pharmacology and Therapeutics·J A JahreH C Neu
Jun 1, 1978·Clinical Pharmacology and Therapeutics·J C PechereM M Pechere
May 1, 1978·The Journal of Antimicrobial Chemotherapy·G KahlmeterC Kamme
Apr 1, 1978·Antimicrobial Agents and Chemotherapy·J J SchentagW J Jusko
Jul 1, 1976·Antimicrobial Agents and Chemotherapy·B R MeyersB Ribner
Nov 1, 1976·Journal of Clinical Pharmacology·F Meunier-CarpentierJ Klastersky
Sep 1, 1975·Antimicrobial Agents and Chemotherapy·G P BodeyD Stewart
Oct 1, 1975·Antimicrobial Agents and Chemotherapy·H LodeP Koeppe
Jan 1, 1975·Antimicrobial Agents and Chemotherapy·V RodriguezR Feld
Apr 1, 1973·Antimicrobial Agents and Chemotherapy·V K SimonV Malerczy
Apr 1, 1973·Antimicrobial Agents and Chemotherapy·K G NaberP O Madsen
Jun 1, 1974·Clinical Pharmacology and Therapeutics·J T ClarkeW M Kirby
Oct 1, 1974·Clinical Pharmacology and Therapeutics·J G Wagner
Dec 1, 1972·Antimicrobial Agents and Chemotherapy·J A WaitzM J Weinstein
May 1, 1973·Clinical Pharmacology and Therapeutics·C RegameyW M Kirby
Jan 1, 1973·Antimicrobial Agents and Chemotherapy·C C Crowe, E Sanders
Apr 1, 1973·Antimicrobial Agents and Chemotherapy·B E Cabana, J G Taggart
Nov 1, 1970·The Journal of Antibiotics·M J WeinsteinJ A Waitz
Feb 1, 1980·Antimicrobial Agents and Chemotherapy·M ChungS Symchowicz

❮ Previous
Next ❯

Citations

Oct 1, 1995·Antimicrobial Agents and Chemotherapy·C LinM N Cayen
Dec 1, 1995·Antimicrobial Agents and Chemotherapy·C C LinM Affrime
Nov 1, 1989·Diabetic Medicine : a Journal of the British Diabetic Association·S M Furler, E W Kraegen
May 31, 1995·Annals of the New York Academy of Sciences·C R Alving

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.